Acadia Pharma (ACAD) Misses Q4 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results
February 28, 2022 4:05 PM EST- Full year 2021 net sales grew to $484.1 million, a 10% increase over 2020
- Resubmitted sNDA for pimavanserin for the treatment of Alzheimer's disease psychosis
- Delivered positive top-line results from the pivotal Phase 3 Lavender trial evaluating trofinetide for the treatment of Rett syndrome
SAN DIEGO--(BUSINESS WIRE)-- Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced financial results for the fourth quarter and full year ended December 31, 2021.
Acadia delivered strong fourth quarter and full year results with an increase in net sales of 10... More
